Dear colleagues, dear friends,
First of all, thank you very much for your participation in the TREOCAPA trial.
The results of the trial have been shared with all the investigating centers and the article, accepted by JAMA Pediatrics, appeared in the April 2026 print issue (February 16 Online First issue).
While the trial was on-going, we sent you a questionnaire on the management of persistent ductus arteriosus and neurodevelopmental follow-up in your center. As we discussed in the recent webinar with investigators of the TREOCAPA and TREOCAPA LT studies in January 2026, we would like to conduct a follow-up survey on management of PDA to assess the impact of the trial results on medical practices in centres participating in the trial.
We sincerely thank you for the time spent answering this questionnaire. It includes 32 questions and requires about 30 minutes to answer. Do not hesitate to contact us to clarify certain questions if necessary.
Gilles Cambonie, MD, PhD
Department of Neonatal Medicine, Montpellier University Hospital Center, France
Andrei Morgan, FRCPCH, MSc, PhD (Epidemiology / Neonatology)
INSERM UMR 1153, Paris, France
Jean-Christophe Rozé, MD, PhD
Coordinator of the European TREOCAPA study
Jennifer Zeitlin
Coordinator of the European TREOCAPA-LT study